JAK2 janus kinase

JAK2 Janus kinase 2 an enzyme that will phosphorylate tyrosine residues on target proteins. JAK2 is bound to the growth hormone receptor but is inactive until the receptor binds the hormone. When hormone binds the receptor, it triggers dimerization and activates JAK2. 

Another family of protein kinases involved in signal transduction via cytokines includes the Janus kinases (Jak kinases). At least four different Jak kinases are known in mammals (Jakl, Jak2, Jak3 and Jak4). A characteristic feature of the structure of Jak kinases is the occurrence of two tyrosine kinase domains (Fig. 11.5). However, only... 

Four mammalian Janus kinase (JAK family members have been identified JAK1, JAK2, JAK3 and Tyk2 with molecular weights ranging from 120 to 140 kDa. 

Incorporation of cytokine in a naive Th lymphocyte receptor activates the route of Janus kinases (JAK1, JAK2, JAK3), transmission proteins for intracellular signals, and activating transcriptions—Signal Transducer and Activator Transcription (STAT)—consequently phosphorylation of receptor tyrosine results. 

This process takes place outside the cell. Dimerization of the extracellular domains of the receptor brings together the intracellular domains as well. Associated with each intracellular domain is a molecule of a protein kinase termed Janus kinase 2 (JAK2) in an unactivated form. Janus kinases have modular structures consisting of four previously described domains (Figure 15.26). 

CSF and IL-3, IL-5 binds with high affinity (452-454). Both subunits are necessary for signal transduction (455). The pathway for signal trai duction includes activation of two Janus kinases (JAKl and JAK2) and the signal transduction/activator STATS (456, 457). 

The Ugand-occupied receptor dimer does not have inherent tyrosine kinase activity but, rather, provides docking sites for 2 molecules of JAK2, a cytoplasmic tyrosine kinase of the Janus kinase family. The juxtaposition of 2 JAK2 molecules leads to trani-phosphorylation and autoactivation of JAK2, with consequent tyrosine phosphorylation of cytoplasmic proteins that mediate downstream signahng events (Figure 55-2). 

Fig. 11.5 Role of growth hormone GH), GH receptor, and the tyrosine kinase Janus kinase 2 (JAK2) in activation of signal transducer and activator of transcription 5b (STATSb) by tyrosine phosphorylation. JAK2 tyrosine phosphorylates itself and multiple tyrosine residues on the cytoplasmic tail of growth hormone receptor (GHR). Several of these sites serve as docking sites that recruit STATSb to the GHR-JAK2 complex. STATSb is then ty-...

Studies proposed that inhibition of the Na /K ATPase pump was responsible for the inhibitory effects of CGs on protein synthesis. They expressed the naturally cardiac glycoside-resistant alphal chain of the murine Na /K ATPase pump, which is about 1,000 times less sensitive for CGs than the human alphal subunit, in human cells [27]. Expression of the murine but not the human alpha chain largely rescued the inhibitory effects of digitoxin on intracellular protein expression. The other study also further indicates that inhibition of the Na /K ATPase pump is responsible for the inhibitiOTi of CGs on protein synthesis. For instance, Na /K ATPase pump activity is inhibited by digitoxin in incubating cells for 4—8 h in a sodium-free buffer. The Na -free buffer inhibited both murine and human Na /K ATPase pump activity as determined by intracellular levels and did not affect cell viability in the timeframe of the experiment, resulting in a decreased expressirai of relatively short-lived proteins such as p53 and Janus kinase 2 (JAK2). 

AZD-1480 (91) was developed by AstraZeneca and studied in Phase I clinical trials for treatment of advanced solid malignancies (the study terminated in 2012) [113]. AZD-1480 is an ATP-competitive inhibitor of Janus kinase 2 (JAK2) - an... 

Comprising a family of four cytoplasmic tyrosine kinase enzymes, JAKl, JAK2, JAKS, and tyrosine kinase 2 (TYK2), the Janus kinases QAKs) are important cell-signaling mediators in myeloid malignancies, inflammatoiy, and autoimmune diseases. Discovery of the V617F mutation in JAK2 in myeloproliferative neoplasm (MPN) patients catalysed rapid advances in JAK... 

---